All News

psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

d Jack Cush, MD

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

d Jack Cush, MD

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A

Read Article
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

d Jack Cush, MD

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

d Jack Cush, MD

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
Doctor Survey: how many Rheumatic/Autoimmune pts do you have on Evusheld (PrEP)?

Dr. John Cush RheumNow ( View Tweet)

ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/n855mvkaoT https://t.co/1nCjL89Bfw

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 218 primary APS w/ Thrombocytopenia in 74 (34%) - such pts had signif. more visceral venous thromboses (13.5% vs. 3.5%), hemolytic anemia (27% vs. 12%), low C3/C4 (26% vs 11%), & higher pregnancy morbidity (HR 8.0, p = 0.0006) https://t.co/U9drB3gWq2 https://t.co/0EwItMO9N1

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery. https://t.co/65llG1nULF https://t.co/YQAJ9tIluF

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available! Smart rules for patients—a patient handout. https://t.co/8yjCwb95c5 https://t.co/baFOavYO99

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnostic Delays in Spondyloarthritis Still Prolonged Previously quoted average delay in diagnosing axSpA may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between 5 and 6 years. https://t.co/6T9pck7nLa https://t.co/nwGBef2Gja

Links:

Dr. John Cush RheumNow ( View Tweet)
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9

Links:

Eric Topol EricTopol ( View Tweet)
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/VvKZaeVumy https://t.co/1shpS0Ajn4

Links:

Dr. John Cush RheumNow ( View Tweet)
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign? https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/W6kjahdLEu https://t.co/QyTmlhb235

Links:

Dr. John Cush RheumNow ( View Tweet)
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain An interesting read from @CreakyJoints. Check it out our synopsis. https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq

Links:

Dr. John Cush RheumNow ( View Tweet)
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!

Links:

Peter Nash drpnash ( View Tweet)

Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/5tomZsaaU6 https://t.co/yAMGY5nlCU

Links:

Dr. John Cush RheumNow ( View Tweet)
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×